Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome

Teresa Cascella, Stefano Palomba, Francesco Giallauria, Ilario De Sio, Annamaria Colao, Gaetano Lombardi, Marcello Orio, Francesco Orio

Research output: Contribution to journalArticle


Polycystic ovary syndrome (PCOS) is considered a sex-specific form of the metabolic syndrome (MetS). Visceral obesity is one of the main diagnostic criteria for the MetS. Patients with MetS have a significantly higher risk for cardiovascular disease (CVD). PCOS is the most common endocrine-metabolic disease of reproductive-age women and PCOS patients are predisposed to an androgen adiposity phenotype, characterized by a prevalent fat accumulation in the abdominal area, and by insulin resistance. PCOS women are exposed to a cluster of metabolic abnormalities and cardiovascular risk factors from a young age, and therefore PCOS patients might represent a high-risk group for developing early-onset CVD. Early signs of CVD have been reported in PCOS patients and correlated to the amount of visceral fat. Visceral fat might represent a new prognostic and therapeutic target to define the cardiovascular risk profile and prevent CVD in PCOS patients.

Original languageEnglish
Pages (from-to)623-632
Number of pages10
JournalFuture Lipidology
Issue number5
Publication statusPublished - 2009


  • Atherogenic dyslipidemia
  • Cardiovascular disease
  • Cardiovascular risk
  • Inflammation
  • Insulin resistance
  • Intima-media thickness
  • Left ventricular hypertrophy
  • Metabolic syndrome
  • Polycystic ovary syndrome
  • Visceral fat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome'. Together they form a unique fingerprint.

  • Cite this

    Cascella, T., Palomba, S., Giallauria, F., De Sio, I., Colao, A., Lombardi, G., Orio, M., & Orio, F. (2009). Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome. Future Lipidology, 4(5), 623-632.